Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma.

Minasian, L M; Szatrowski, T P; Rosenblum, M; Steffens, T; Morrison, M E; Chapman, P B; Williams, L; Nathan, C F; Houghton, A N

Minasian, L M; Szatrowski, T P; Rosenblum, M; Steffens, T; Morrison, M E; Chapman, P B; Williams, L; Nathan, C F; Houghton, A N.

Affiliation

Minasian LM; Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Blood ; 83(1): 56-64, 1994 Jan 01.

Article in En | MEDLINE | ID: mdl-8274754

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Gangliosides/immunology; Melanoma/therapy; Tumor Lysis Syndrome/etiology; Tumor Necrosis Factor-alpha/adverse effects; Adult; Aged; Antibodies, Monoclonal/administration & dosage; Female; Humans; Male; Melanoma/pathology; Melanoma/secondary; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine/pharmacology; Necrosis; Neutrophils/drug effects; Neutrophils/metabolism; Recombinant Proteins/adverse effects; Tetradecanoylphorbol Acetate/pharmacology; Tumor Necrosis Factor-alpha/administration & dosage

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tumor Lysis Syndrome / Antineoplastic Combined Chemotherapy Protocols / Tumor Necrosis Factor-alpha / Gangliosides / Melanoma / Antibodies, Monoclonal Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 1994 Document type: Article Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links